Effect of the sphingosine kinase 1 selective inhibitor, PF-543 on arterial and cardiac remodelling in a hypoxic model of pulmonary arterial hypertension

Cellular Signalling

Volumn 28, Issue 8, 2016, Pages 946-955

  MacRitchie, Neil ^a   Volpert, Giora ^b   Al Washih, Mohammed ^a   Watson, David G ^a   Futerman, Anthony H ^b   Kennedy, Simon ^c   Pyne, Susan ^a   Pyne, Nigel J ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Hypertrophy; Hypoxia; Pulmonary arterial hypertension; Sphingosine 1 phosphate; Sphingosine kinase; Vascular remodelling

Indexed keywords

CASPASE 3; CASPASE 7; CERAMIDE GLUCOSYLTRANSFERASE; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENZYME INHIBITOR; FINGOLIMOD; ISOPROTEIN; PF 543; PHOSPHODIESTERASE V INHIBITOR; PROTEIN KINASE; PROTEIN P53; RB 005; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; 1-(4-OCTYLPHENETHYL)PIPERIDIN-4-OL; BIOLOGICAL MARKER; PF-543; PHOSPHOTRANSFERASE; PIPERIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; SPHINGOSINE KINASE; SULFONE;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; HEART ATRIUM REMODELING; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; MOUSE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SMOOTH MUSCLE CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BLOOD; BODY WEIGHT; C57BL MOUSE; CELL CULTURE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; HEART VENTRICLE; HEART VENTRICLE REMODELING; HEK293 CELL LINE; HYPOXIA; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PRESSURE; PULMONARY ARTERY; SIGNAL TRANSDUCTION;

ANIMALS; BIOMARKERS; BODY WEIGHT; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; HEART VENTRICLES; HEK293 CELLS; HUMANS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; HYPOXIA; MICE, INBRED C57BL; MODELS, BIOLOGICAL; MYOCYTES, SMOOTH MUSCLE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PIPERIDINES; PRESSURE; PULMONARY ARTERY; PYRROLIDINES; SIGNAL TRANSDUCTION; SULFONES; VENTRICULAR REMODELING;

EID: 84966750089     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2016.03.014     Document Type: Article

References (37)

1. Spiegel S., Milstien S. Sphingosine-1-phosphate: an enigmatic signaling lipid. Nat. Rev. Mol. Cell Biol. 2003, 4:397-407.
2. Blaho V.A., Hla T. An update on the biology of sphingosine 1-phosphate receptors. J. Lipid Res. 2014, 55:1596-1608.
3. Hait N.C., Allegood J., Maceyka M., Strub G.M., Harikumar K.B., Singh S.K., Luo C., Marmorstein R., Kordula T., Milstein S., Spiegel S. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009, 325:1254-1257.
4. Stiban J., Tidhar R., Futerman A.H. Ceramide synthases: roles in cell physiology and signaling. Adv. Exp. Med. Biol. 2010, 688:60-71.
5. Degagné E., Saba J.D. S1pping fire: sphingosine-1-phosphate signaling as an emerging target in inflammatory bowel disease and colitis-associated cancer. Clin. Exp. Gastroenterol. 2014, 7:205-214.
6. Benza R.L., Miller D.P., Barst R.J., Badesch D.B., Frost A.E., McGoon M.D. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012, 142:448-456.
7. Ahmad M., Long J.S., Pyne N.J., Pyne S. The effect of hypoxia on Lipid phosphate receptor and sphingosine kinase expression and mitogen activated protein kinase signaling in human pulmonary smooth muscle cells. Prostaglandins and Other Lipid Mediators 2006, Vol. 79:278-286.
8. Chen J., Tang H., Sysol J.R., Moreno-Vinasco L., Shioura K.M., Chen T., Gorshkova I., Wang L., Huang L.S., Usatyuk P.V., Sammani S., Zhou G., Raj J.U., Garcia J.G., Berdyshev E., Yuan J.X., Natarajan V., Machado R.F. The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2014, 190:1032-1043.
9. Kurzyna M., Zyłkowska J., Fijałkowska A., Florczyk M., Wieteska M., Kacprzak A., Burakowski J., Szturmowicz M., Wawrzyńska L., Torbicki A. Characteristics and prognosis of patients with decompensated right ventricular failure during the course of pulmonary hypertension. Kardiol. Pol. 2008, 66:1033-1039.
10. Sztrymf B., Souza R., Bertoletti L., Jaïs X., Sitbon O., Price L.C., Simonneau G., Humbert M. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur. Respir. J. 2010, 35:1286-1293.
11. Haddad F., Peterson T., Fuh E., Kudelko K.T., de Jesus Perez V., Skhiri M., Vagelos R., Schnittger I., Denault A.Y., Rosenthal D.N., Doyle R.L., Zamanian R.T. Characteristics and outcome after hospitalization for acute right heart failure in patients with pulmonary arterial hypertension. Circ. Heart Fail. 2011, 4:692-699.
12. Campo A., Mathai S.C., Le Pavec J., Zaiman A.L., Hummers L.K., Boyce D., Housten T., Lechtzin N., Chami H., Girgis R.E., Hassoun P.M. Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. Eur. Respir. J. 2011, 38:359-367.
13. Li Z., Bing O.H., Long X., Robinson K.G., Lakatta E.G. Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat. Am. J. Phys. 1997, 272:H2313-H2319.
14. Olivetti G., Abbi R., Quaini F., Kajstura J., Cheng W., Nitahara J.A., et al. Apoptosis in the failing human heart. N. Engl. J. Med. 1997, 336:1131-1141.
15. Nadal-Ginard B., Kajstura J., Leri A., Anversa P. Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ. Res. 2003, 92:139-150.
16. Campian M.E., Vernberne H.J., Hardzivenka M., de Bruin K., Slewaness M., van Den M.J., Hoff J.M., Ruijter B.L., Eck-Smit van, de Bakker J.M., Tan H.L. Serial noninvasive assessment of apoptosis during right ventricular disease progression in rats. J. Nucl. Med. 2009, 50:1371-1377.
17. Zuo X.R., Wang Q., Cao Q., Yu Y.Z., Wang H., Bi L.Q., Xie W.P., Wang H. Nicorandil prevents right ventricular remodeling by inhibiting apoptosis and lowering pressure overload in rats with pulmonary arterial hypertension. PLoS One 2012, 7.
18. D.A Vessey, Li L., Jin Z.Q., Kelley M., Honbo N., Zhang J., Karliner J.S. A sphingosine kinase form 2 knockout sensitizes mouse myocardium to ischemia/reoxygenation injury and diminishes responsiveness to ischemic preconditioning. Oxidative Med. Cell. Longev. 2011.
19. Zhang F., Xia Y., Yan W., Zhang H., Zhou F., Zhao S., Wang W., Zhu D., Xin C., Lee Y., Zhang L., He Y., Gao E., Teo L. Sphingosine 1-phosphate signaling contributes to cardiac inflammation, dysfunction, and remodeling following myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 2015, 310:H250-H261.
20. Hla T., Brinkmann V. Sphingosine 1-phosphate (S1P): physiology and the effects of S1P receptor modulation. Neurology 2011, 76.
21. Tonelli F., Lim K.G., Loveridge C., Long J., Pitson S.M., Tigyi G., Bittman R., Pyne S., Pyne N.J. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell. Signal. 2010, 22:1536-1542.
22. Byun H.S., Pyne S., MacRitchie N., Pyne N.J., Bittman R. Novel sphingosine containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells. Med. Chem. Commun. 2013, 4:1394-1399.
23. Baek D.J., MacRitchie N., Pyne N.J., Pyne S., Bittman R. Synthesis of selective inhibitors of sphingosine kinase 1. Chem. Commun. (Camb) 2013, 49:2136-2138.
24. McGrath J.C., Drummond G.B., McLachlan E.M., Kilkenny C., Wainwright C.L. Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br. J. Pharmacol. 2010, 160:1573-1576.
25. Farmer D.G.S., Ewart M.-A., Mair K.M., Kennedy S. Soluble receptor for advanced glycation end products (sRAGE) attenuates haemodynamic changes to chronic hyoxia in the mouse. Pulm. Pharmacol. Ther. 2014, 29:7-14.
26. Huwiler A., Döll F., Ren S., Klawitter S., Greening A., Römer I., Bubnova S., Reinsberg L., Pfeilschifter J. Histamine increases sphingosine kinase-1 expression and activity in the human arterial endothelial cell line EA.hy 926 by a PKC-alpha-dependent mechanism. Biochim. Biophys. Acta 2006, 1761:367-376.
27. Tidhar R., Sims K., Rosenfeld-Gur E., Shaw W., Futerman A.H. A rapid ceramide synthase activity using NBD-sphinganine and solid phase extraction. J. Lipid Res. 2015, 56:193-199.
28. Lahiri S., Park H., Laviad E.L., Lu X., Bittman R., Futerman A.H. Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an acyl-CoA chain Length-dependent manner. J. Biol. Chem. 2009, 284:16090-16098.
29. Loveridge C., Tonelli F., Leclercq T., Lim K.G., Long J.S., Berdyshev E., Tate R., Natarajan V., Pitson S.M., Pyne N.J., Pyne S. The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells. J. Biol. Chem. 2010, 285:38841-38852.
30. Pak O., Aldashev A., Welsh D., Peacock A. The effects of hypoxia on the cells of the pulmonary vasculature. Eur. Respir. J. 2007, 30:364-372.
31. Dempsie Y., Morecroft I., Welsh D.J., MacRitchie N.A., Herold N., Loughlin L., Nilsen M., Peacock A.J., Harmar A., Bader M., MacLean M.R. Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice. Circulation 2008, 117:2928-2937.
32. Morecroft I., Dempsie Y., Bader M., Walther D.J., Kotnik K., Loughlin L., Nilsen M., M.R MacLean Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension 2007, 49:232-236.
33. Allende M.L., Sasaki T., Kawai H., Olivera A., Mi Y., van Echten-Deckert G., Hajdu R., Rosenbach M., Keohane C.A., Mandala S., Spiegel S., Proia R.L. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J. Biol. Chem. 2004, 279:52487-52492.
34. Mizugishi K., Yamashita T., Olivera A., Miller G.F., Spiegel S., Proia R.L. Essential role for sphingosine kinases in neural and vascular development. Mol. Cell. Biol. 2005, 25:11113-11121.
35. Cingolani F., Casasampere M., Sanllehí P., Casas J., Bujons J., Fabrias G. Inhibition of dihydroceramide desaturase activity by the sphingosine kinase inhibitor SKI II. J. Lipid Res. 2014, 55:1711-1720.
36. Germain Affar M., D'Amours D., Dixit V.M., Salvesen G.S., Poirier G.G. Cleavage of automodified poly(ADP-ribose) polymerase during apoptosis. evidence for involvement of caspase-7. J. Biol. Chem. 1999, 274:28379-28384.
37. Bogaard H.J., Natarajan R., Henderson S.C., Long C.S., Kraskauskas D., Smithson L., Ockaili R., McCord J.M., Voelkel N.F. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 2009, 120:1951-1960.